Smart companies are raising money to advance drug development programs while investors are pouring cash into the biotechnology industry. The latest to raise private capital: Oncobiologics, Ra Pharmaceuticals, RaNA Therapeutics and SutroVax.
Oncobiologics founder and CEO Pankaj Mohan told Scrip that the company raised $31m from institutional investors, including hedge funds and mutual funds, to ramp up production of its biosimilars and to increase its visibility among Wall Street-focused investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?